Alternative treatments for melanoma: targeting BCL-2 family members to de-bulk and kill cancer stem cells

For the first time new treatments in melanoma have produced significant responses in advanced diseases, but 30–90% of melanoma patients do not respond or eventually relapse after the initial response to the current treatments. The resistance of these melanomas is likely due to tumor heterogeneity, w...

Full description

Saved in:
Bibliographic Details
Published in:J Invest Dermatol
Main Authors: Mukherjee, Nabanita, Schwan, Josianna V., Fujita, Mayumi, Norris, David A., Shellman, Yiqun G.
Format: Artigo
Language:Inglês
Published: 2015
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4537369/
https://ncbi.nlm.nih.gov/pubmed/25947358
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/jid.2015.145
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items